NCT06085053

A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TQA3038 Injection in Healthy Adult Subjects.

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 54 (estimated)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics. In the single ascending dose (SAD) part, healthy adult subjects will receive one dose of TQA3038 or placebo, administered subcutaneously (SC).

Conditions

• Chronic Hepatitis b

Interventions

Type	Name	Description
DRUG	TQA3038 injection	TQA3038 is an injection.
DRUG	TQA3038 injection matching placebo	Placebo injection contains no active substance.

Timeline

• Start date: 2023-11-30
• Primary completion: 2024-12-01
• Completion: 2025-12-01
• First posted: 2023-10-16
• Last updated: 2023-12-05

Locations

1 site across 1 country: China